[Topical carbonic anhydrase inhibitors in the treatment of glaucoma].

Systemically administered carbonic anhydrase inhibitors have been in clinical use since the 1950's. Their use and side effects have been reviewed extensively. Our review summarizes the development of topically administered carbonic anhydrase inhibitors in patients with glaucoma. Moreover, it documents clinical trials leading to the present choice of dorzolamide (MK-507), which is now being reviewed for worldwide approval for marketing by 1995.